A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy
Latest Information Update: 22 Mar 2022
At a glance
- Drugs Tadalafil (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 11 Mar 2022 According to a PTC Therapeutics media release, results evaluating associations between Deflazacort vs Prednisone/prednisolone and disease progression markers in subgroup of patients with Duchenne Muscular Dystrophy (NCT01826487, NCT01865084, NCT00592553, NCT01254019) will be presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2022. Abstract is available on the MDA Conference website.
- 25 Feb 2016 Planned End Date changed from 1 Apr 2018 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 10 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.